{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:38:01Z","timestamp":1787726281942,"version":"build-2784847793"},"reference-count":57,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"49","license":[{"start":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12,5]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Contrast-induced nephropathy (CIN), a common complication of percutaneous coronary intervention (PCI), adversely affects clinical outcomes by extending hospital stays and increasing healthcare costs. Importantly, CIN is linked to poor prognosis in acute myocardial infarction (AMI) patients. This study evaluated the preventive effect of pre-procedural sodium-glucose cotransporter-2 (SGLT2) inhibitors administration on CIN incidence in AMI patients who received PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>A systematic search of PubMed, Web of science, and the Cochrane Library was performed for studies published up to December 12, 2024. Observational studies and clinical trials investigating pre-procedural SGLT2 inhibitors use in PCI-treated AMI patients were included. Following PRISMA guidelines, 2 researchers independently screened the literature, extracted the data, and assessed the bias risk. Data synthesis utilized Review Manager 5.3 with a random-effects model to address heterogeneity. The primary outcomes included CIN incidence (95% confidence intervals (CI)). The secondary outcomes included all-cause mortality, major adverse cardiovascular events (MACE), recurrent myocardial infarction, and heart failure (HF) readmission, which were analyzed via risk ratios(RR) and I\u00b2 statistics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      Five studies involving 3301 patients (SGLT2 inhibitors group: 665; control: 2636) were analyzed. Compared with the control group, the SGLT2 inhibitors group demonstrated significantly lower risks of CIN (RR: 0.55, 95% CI: 0.41\u20130.73,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005&lt;\u2005.0001), all-cause mortality (RR: 0.49, 95% CI: 0.29\u20130.81,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.005), MACE (RR: 0.33, 95% CI: 0.17\u20130.65,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.01), and HF readmission (RR: 0.30, 95% CI: 0.16\u20130.56,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.0001). No significant difference was observed in the recurrent myocardial infarction rates (RR: 0.88, 95% CI: 0.38\u20132.06,\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2005=\u2005.77).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Pre-procedural SGLT2 inhibitors use significantly reduces CIN incidence, mortality, MACE, and HF readmission in PCI-treated AMI patients, suggesting potential cardiorenal protective benefits.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000044215","type":"journal-article","created":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T22:01:21Z","timestamp":1764972081000},"page":"e44215","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Pre-PCI SGLT2 inhibitors and contrast-induced nephropathy in acute myocardial infarction: A meta-analysis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3092-0905","authenticated-orcid":false,"given":"Yue","family":"Li","sequence":"first","affiliation":[{"name":"Department of Cardiology, The People\u2019s Hospital of Rongchang District, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanyao","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The People\u2019s Hospital of Rongchang District, Chongqing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-4964-2289","authenticated-orcid":false,"given":"Rui","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Oncology, The People\u2019s Hospital of Rongchang District, Chongqing, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260523","doi-asserted-by":"crossref","first-page":"101048","DOI":"10.1016\/j.jacadv.2024.101048","article-title":"The price we pay: cardiogenic shock after acute myocardial infarction.","volume":"3","author":"Vallabhajosyula","year":"2024","journal-title":"JACC Adv"},{"key":"R2-20260523","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/eurheartj\/ehy655","article-title":"Fourth universal definition of myocardial infarction (2018).","volume":"39","author":"Thygesen","year":"2018","journal-title":"Eur Heart J"},{"key":"R3-20260523","doi-asserted-by":"crossref","first-page":"e9785","DOI":"10.1097\/MD.0000000000009785","article-title":"Cardiac rehabilitation in acute myocardial infarction patients after percutaneous coronary intervention: a community-based study.","volume":"97","author":"Zhang","year":"2018","journal-title":"Medicine (Baltim)"},{"key":"R4-20260523","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1001\/jama.2022.0358","article-title":"Diagnosis and treatment of acute coronary syndromes: a review.","volume":"327","author":"Bhatt","year":"2022","journal-title":"JAMA"},{"key":"R5-20260523","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1177\/08465371221083970","article-title":"Canadian association of radiologists guidance on contrast-associated acute kidney injury.","volume":"73","author":"Macdonald","year":"2022","journal-title":"Can Assoc Radiol J"},{"key":"R6-20260523","doi-asserted-by":"crossref","first-page":"261","DOI":"10.4093\/dmj.2014.38.4.261","article-title":"A novel therapeutic agent for type 2 diabetes mellitus: SGLT2 inhibitor.","volume":"38","author":"Jung","year":"2014","journal-title":"Diabetes Metab J"},{"key":"R7-20260523","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.2337\/dc18-0588","article-title":"SGLT2 inhibitors in combination therapy: from mechanisms to clinical considerations in type 2 diabetes management.","volume":"41","author":"van Baar","year":"2018","journal-title":"Diabetes Care"},{"key":"R8-20260523","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1056\/NEJMc1600827","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes.","volume":"374","author":"Sarafidis","year":"2016","journal-title":"N Engl J Med"},{"key":"R9-20260523","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1161\/CIRCULATIONAHA.116.021887","article-title":"Sodium glucose cotransporter 2 inhibitors in the treatment of diabetes mellitus: cardiovascular and kidney effects, potential mechanisms, and clinical applications.","volume":"134","author":"Heerspink","year":"2016","journal-title":"Circulation"},{"key":"R10-20260523","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.redox.2017.12.019","article-title":"Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission.","volume":"15","author":"Zhou","year":"2018","journal-title":"Redox Biol"},{"key":"R11-20260523","doi-asserted-by":"crossref","first-page":"102288","DOI":"10.1016\/j.redox.2022.102288","article-title":"Empagliflozin attenuates cardiac microvascular ischemia\/reperfusion through activating the AMPK\u03b11\/ULK1\/FUNDC1\/mitophagy pathway.","volume":"52","author":"Cai","year":"2022","journal-title":"Redox Biol"},{"key":"R12-20260523","doi-asserted-by":"crossref","first-page":"F767","DOI":"10.1152\/ajprenal.00565.2018","article-title":"Empagliflozin attenuates diabetic tubulopathy by improving mitochondrial fragmentation and autophagy.","volume":"317","author":"Lee","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"key":"R13-20260523","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1161\/CIRCULATIONAHA.118.038881","article-title":"Possible mechanism of hematocrit elevation by sodium glucose cotransporter 2 inhibitors and associated beneficial renal and cardiovascular effects.","volume":"139","author":"Sano","year":"2019","journal-title":"Circulation"},{"key":"R14-20260523","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease.","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"issue":"Suppl 2","key":"R15-20260523","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.2337\/dcS15-3006","article-title":"SGLT2 inhibitors and the diabetic kidney.","volume":"39","author":"Fioretto","year":"2016","journal-title":"Diabetes Care"},{"key":"R16-20260523","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s10741-021-10096-8","article-title":"SGLT2 inhibitors break the vicious circle between heart failure and insulin resistance: targeting energy metabolism.","volume":"27","author":"Wang","year":"2022","journal-title":"Heart Fail Rev"},{"key":"R17-20260523","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10741-020-09921-3","article-title":"Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization.","volume":"25","author":"Hattori","year":"2020","journal-title":"Heart Fail Rev"},{"key":"R18-20260523","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes.","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"R19-20260523","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12933-020-01071-y","article-title":"SGLT2i: beyond the glucose-lowering effect.","volume":"19","author":"Ni","year":"2020","journal-title":"Cardiovasc Diabetol"},{"key":"R20-20260523","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction.","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"R21-20260523","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes.","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"R22-20260523","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"Canagliflozin and cardiovascular and renal events in type 2 diabetes.","volume":"377","author":"Neal","year":"2017","journal-title":"N Engl J Med"},{"key":"R23-20260523","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy.","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"R24-20260523","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.kint.2019.09.013","article-title":"The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.","volume":"97","author":"van Bommel","year":"2020","journal-title":"Kidney Int"},{"key":"R25-20260523","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1161\/CIRCULATIONAHA.116.024764","article-title":"Use of sodium glucose cotransporter 2 inhibitors in the hands of cardiologists: with great power comes great responsibility.","volume":"134","author":"Cherney","year":"2016","journal-title":"Circulation"},{"key":"R26-20260523","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jclinepi.2009.06.006","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.","volume":"62","author":"Liberati","year":"2009","journal-title":"J Clin Epidemiol"},{"key":"R27-20260523","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0735-1097(00)00804-4","article-title":"Myocardial infarction redefined \u2013 a consensus document of the Joint European Society of Cardiology\/American College of Cardiology Committee for the redefinition of myocardial infarction.","volume":"36","author":"Alpert","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"R28-20260523","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00228-024-03623-7","article-title":"Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients.","volume":"80","author":"Cai","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"R29-20260523","doi-asserted-by":"crossref","first-page":"29","DOI":"10.33963\/v.kp.98260","article-title":"Potential renoprotective effect of SGLT2 inhibitors against contrast-induced AKI in diabetic STEMI patients undergoing primary PCI.","volume":"82","author":"K\u00fclt\u00fcrsay","year":"2024","journal-title":"Kardiol Pol"},{"key":"R30-20260523","doi-asserted-by":"crossref","first-page":"110766","DOI":"10.1016\/j.diabres.2023.110766","article-title":"Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: insight from SGLT2-I AMI PROTECT registry.","volume":"202","author":"Paolisso","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"R31-20260523","doi-asserted-by":"crossref","first-page":"106597","DOI":"10.1016\/j.phrs.2022.106597","article-title":"Outcomes in diabetic patients treated with SGLT2-inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT registry.","volume":"187","author":"Paolisso","year":"2023","journal-title":"Pharmacol Res"},{"key":"R32-20260523","doi-asserted-by":"crossref","first-page":"E898","DOI":"10.59958\/hsf.7627","article-title":"Efficacy and safety of canagliflozin in STEMI patients with type 2 diabetes after PCI: a retrospective study.","volume":"27","author":"Chen","year":"2024","journal-title":"Heart Surg Forum"},{"key":"R33-20260523","doi-asserted-by":"crossref","first-page":"e150322202194","DOI":"10.2174\/1573403X1801220315090538","article-title":"An overview of current advances in contemporary percutaneous coronary intervention.","volume":"18","author":"Alkhalil","year":"2022","journal-title":"Curr Cardiol Rev"},{"key":"R34-20260523","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1016\/j.amjcard.2019.02.015","article-title":"In-hospital outcomes after percutaneous coronary intervention for acute coronary syndrome with cardiogenic shock (from a Japanese nationwide registry [J-PCI registry]).","volume":"123","author":"Kubo","year":"2019","journal-title":"Am J Cardiol"},{"key":"R35-20260523","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1038\/sj.ki.5000366","article-title":"Contrast-induced nephrotoxicity: clinical landscape.","volume":"69","author":"Katzberg","year":"2006","journal-title":"Kidney Int Suppl"},{"key":"R36-20260523","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1016\/S0140-6736(21)02326-6","article-title":"A contemporary simple risk score for prediction of contrast-associated acute kidney injury after percutaneous coronary intervention: derivation and validation from an observational registry.","volume":"398","author":"Mehran","year":"2021","journal-title":"Lancet"},{"key":"R37-20260523","doi-asserted-by":"crossref","first-page":"862534","DOI":"10.3389\/fmed.2022.862534","article-title":"The incidence of contrast-induced nephropathy and the need for dialysis in patients receiving angiography: a systematic review and meta-analysis.","volume":"9","author":"Wu","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"R38-20260523","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3390\/jcm8020147","article-title":"Does resveratrol play a role in decreasing the inflammation associated with contrast-induced nephropathy in rat model?","volume":"8","author":"Chen","year":"2019","journal-title":"J Clin Med"},{"key":"R39-20260523","doi-asserted-by":"crossref","first-page":"332","DOI":"10.5301\/jn.5000007","article-title":"High-sensitivity C-reactive protein predicts contrast-induced nephropathy after primary percutaneous coronary intervention.","volume":"25","author":"Liu","year":"2012","journal-title":"J Nephrol"},{"key":"R40-20260523","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1159\/000430770","article-title":"Contrast medium-induced acute kidney injury.","volume":"5","author":"Sadat","year":"2015","journal-title":"Cardiorenal Med"},{"key":"R41-20260523","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(19)32563-2","article-title":"Acute kidney injury.","volume":"394","author":"Ronco","year":"2019","journal-title":"Lancet"},{"key":"R42-20260523","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1053\/j.ajkd.2008.11.034","article-title":"Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis.","volume":"53","author":"Coca","year":"2009","journal-title":"Am J Kidney Dis"},{"key":"R43-20260523","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/eurheartj\/ehn096","article-title":"The timing of development and subsequent clinical course of heart failure after a myocardial infarction.","volume":"29","author":"Torabi","year":"2008","journal-title":"Eur Heart J"},{"key":"R44-20260523","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1016\/j.jacc.2016.01.069","article-title":"Relationship between infarct size and outcomes following primary PCI: patient-level analysis from 10 randomized trials.","volume":"67","author":"Stone","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"R45-20260523","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1093\/eurheartj\/eht090","article-title":"Myocardial reperfusion injury: looking beyond primary PCI.","volume":"34","author":"Fr\u00f6hlich","year":"2013","journal-title":"Eur Heart J"},{"key":"R46-20260523","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1007\/s10741-010-9177-3","article-title":"STEMI and heart failure in the elderly: role of adverse remodeling.","volume":"15","author":"Jelani","year":"2010","journal-title":"Heart Fail Rev"},{"key":"R47-20260523","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5527\/wjn.v6.i3.86","article-title":"Contrast-induced acute kidney injury: a review of practical points.","volume":"6","author":"Ozkok","year":"2017","journal-title":"World J Nephrol"},{"key":"R48-20260523","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1080\/00015385.2023.2198937","article-title":"Prediction of the development of contrast-induced nephropathy following percutaneous coronary artery intervention by machine learning.","volume":"78","author":"Ma","year":"2023","journal-title":"Acta Cardiol"},{"key":"R49-20260523","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure.","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"R50-20260523","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/j.jacc.2022.03.353","article-title":"Sodium glucose cotransporter-2 inhibition for acute myocardial infarction.","volume":"79","author":"Udell","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R51-20260523","doi-asserted-by":"crossref","first-page":"4043","DOI":"10.1093\/eurheartj\/ehad192","article-title":"2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.","volume":"44","author":"Marx","year":"2023","journal-title":"Eur Heart J"},{"key":"R52-20260523","first-page":"1846","article-title":"A literature case study of 22 cases of acute kidney injury induced by sodium-glucose cotransporter 2 inhibitors.","volume":"43","author":"Zhao","year":"2023","journal-title":"Chin J Hosp Pharm"},{"key":"R53-20260523","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1111\/dom.14801","article-title":"Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: a systematic review and network meta-analysis.","volume":"24","author":"Yang","year":"2022","journal-title":"Diabetes Obes Metab"},{"key":"R54-20260523","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s40256-024-00684-y","article-title":"Efficacy of chronic use of sodium-glucose co-transporter 2 inhibitors on the prevention of contrast-induced acute kidney injury in patients with type 2 diabetes mellitus following coronary procedures: a systematic review and meta-analysis.","volume":"25","author":"Dimitriadis","year":"2025","journal-title":"Am J Cardiovasc Drugs"},{"key":"R55-20260523","doi-asserted-by":"crossref","first-page":"105836","DOI":"10.1016\/j.phrs.2021.105836","article-title":"SGLT-2 inhibitors reduce the risk of cerebrovascular\/cardiovascular outcomes and mortality: a systematic review and meta-analysis of retrospective cohort studies.","volume":"172","author":"Mascolo","year":"2021","journal-title":"Pharmacol Res"},{"key":"R56-20260523","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s40256-022-00545-6","article-title":"SGLT2 inhibitors: new hope for the treatment of acute myocardial infarction?","volume":"22","author":"Wu","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"R57-20260523","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.072009","article-title":"Derivation and validation of the PRECISE-HBR score to predict bleeding after percutaneous coronary intervention.","volume":"151","author":"Gragnano","year":"2025","journal-title":"Circulation"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044215","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T10:00:40Z","timestamp":1779530440000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044215"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,5]]},"references-count":57,"journal-issue":{"issue":"49","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044215","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,5]]},"assertion":[{"value":"2025-02-26","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-07-11","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}